Clavis Pharma announces $380 million agreement to develop its CP-4126 drug candidate

NewsGuard 100/100 Score
Editorial Checklist Reviewed
Nov 24 2009Clavis Pharma ASA

Clavis Pharma ASA (OSE: CLAVIS), the clinical stage oncology focused pharmaceutical company, announced today a $380 million agreement for the further development and commercialisation of its drug candidate, CP-4126, currently in Phase II development in pancreatic cancer.

A meeting for investors, analysts and press will take place in Oslo at 10.00 CET today, 24 November 2009 at Hotel Continental, Stortingsgaten 24, Oslo, Norway.

An international conference call will take place at 12:00 CET -- details are given below.

Access the audio for the meeting by dialling the following and quoting confirmation code 4956336:

+47 2415 9758 (from Norway) +44 (0)20 7806 1966 (International)

Source:

Clavis Pharma ASA

Posted in: Pharmaceutical News

Tags: , , ,

Comments (0)

Suggested Reading

Sleep apnea prevalent among cardio-oncology patients, study shows
AI chatbot offers accurate answers to radiation oncology queries
Revolutionizing brain tumor treatment: the rise of AI in neuro-oncology
Recycled food waste may be contaminated with pharmaceutical residues, research reveals
Linking lifestyle to longevity: How diet and hypertension sway risks for heart disease and cancer
Advances and hurdles: The impact of AI on oncology care efficiency and mortality rates
FDA approval of Anktiva heralds a new era in the treatment of BCG-unresponsive non–muscle-invasive bladder cancer
New Lancet Commission on Breast Cancer: Transforming breast cancer care globally

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Study evaluates large language models for autocontouring in head and neck radiotherapy